GlassScriptPhysician profile
Walter Kobasa
NPI 1891876009
$316.98
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $94.59 · 2021: $86.23 · 2022: $33.59.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $62.60 | 2020-2021 | |
| Avion Pharmaceuticals | $54.35 | 2019-2022 | |
| Abbvie INC. | $28.29 | 2020 | |
| Lupin INC. | $25.99 | 2020-2021 | |
| Covidien LP | $22.60 | 2019 | |
| Aspira Women'S Health INC | $21.05 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.92 | 2022 | |
| Agile Therapeutics, INC. | $19.86 | 2021 | |
| Hologic Sales and Service, LLC | $15.82 | 2019 | |
| Mission Pharmacal Company | $12.29 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $11.96 | 2020 | |
| Allergan, INC. | $11.18 | 2019 | |
| Scynexis, INC. | $11.07 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Kobasa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.